Recognizing that developmental research funds are an integral part of the SPORE, we commit $205,000 per year to these endeavors. This represents a significant percent in the budget of the UM Prostate SPORE and reflects the continued commitment of this program to the development of innovative translational research in prostate cancer. The focus of the Developmental Research Program (DRP) is to provide investigators the resources to generate preliminary data for the submission of an R01 grant application or an equivalent proposal Investigators from outside the field of prostate cancer are encouraged to apply through campus-wide announcements as well as through personal interactions with the SPORE investigators. We developed a stepwise proposal solicitation and review process for pilot projects utilizing an NIH-type PHS 398 format that has been streamlined for rapid turnaround of research proposals and which recognizes that these projects may have little preliminary data. Investigators may apply for pilot project grants ($40,000 - $50,000 each) or seed grants ($5,000 - $10,000 each). In addition, we set aside funds for summer student projects ($5,000 each). Since 1995, we have invested $3.5 million in our DRP, funding a total of 83 investigators though 68 pilot projects, 63 seed grants and 35 summer student projects. These awards have led to over $32 million in subsequent SPORE and non-SPORE peer-reviewed funding and 127 published manuscripts. During this current grant cycle, we funded 51 projects: 16 pilot projects ($50K each), 4 seed grants ($10K each) and 35 summer student projects ($5K each). Drs. Maha Hussain and Mark Day serve as co-Directors for the DRP. Dr. Hussain is a Professor of Internal Medicine and Urology and is internationally recognized for her clinical research expertise in prostate cancer. Dr. Hussain participates with the Oncology Training Grant. She serves as the

Public Health Relevance

The UM SPORE recognizes the importance of the Developmental Research Program as an integral part of the of our prostate cancer research community. Through a process of rigorous peer review, we encourage innovative and high risk/high reward prostate cancer research by established and new investigators to the field. Our ultimate goal is to decrease the morbidity and mortality of prostate cancer through innovative research.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Specialized Center (P50)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-RPRB-7 (M1))
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Michigan Ann Arbor
Ann Arbor
United States
Zip Code
Udager, Aaron M; DeMarzo, Angelo M; Shi, Yang et al. (2016) Concurrent nuclear ERG and MYC protein overexpression defines a subset of locally advanced prostate cancer: Potential opportunities for synergistic targeted therapeutics. Prostate 76:845-53
Kaushik, Akash K; Shojaie, Ali; Panzitt, Katrin et al. (2016) Inhibition of the hexosamine biosynthetic pathway promotes castration-resistant prostate cancer. Nat Commun 7:11612
Feng, Felix Y; Kothari, Vishal (2016) Driven to metastasize: Kinases as potential therapeutic targets in prostate cancer. Proc Natl Acad Sci U S A 113:473-5
Allen, Eliezer M Van; Robinson, Dan; Morrissey, Colm et al. (2016) A comparative assessment of clinical whole exome and transcriptome profiling across sequencing centers: Implications for precision cancer medicine. Oncotarget :
Niknafs, Yashar S; Han, Sumin; Ma, Teng et al. (2016) The lncRNA landscape of breast cancer reveals a role for DSCAM-AS1 in breast cancer progression. Nat Commun 7:12791
Fabris, Linda; Ceder, Yvonne; Chinnaiyan, Arul M et al. (2016) The Potential of MicroRNAs as Prostate Cancer Biomarkers. Eur Urol 70:312-22
Shukla, Sudhanshu; Zhang, Xiang; Niknafs, Yashar S et al. (2016) Identification and Validation of PCAT14 as Prognostic Biomarker in Prostate Cancer. Neoplasia 18:489-99
Tomlins, Scott A; Day, John R; Lonigro, Robert J et al. (2016) Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment. Eur Urol 70:45-53
Roychowdhury, Sameek; Chinnaiyan, Arul M (2016) Translating cancer genomes and transcriptomes for precision oncology. CA Cancer J Clin 66:75-88
Day, Kathleen C; Lorenzatti Hiles, Guadalupe; Kozminsky, Molly et al. (2016) HER2 and EGFR overexpression support metastatic progression of prostate cancer to bone. Cancer Res :

Showing the most recent 10 out of 45 publications